Geneva Capital Management LLC Sells 1,415 Shares of Edwards Lifesciences Co. (NYSE:EW)

Geneva Capital Management LLC trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 16,322 shares of the medical research company’s stock after selling 1,415 shares during the quarter. Geneva Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,077,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. GSA Capital Partners LLP bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $481,000. Entropy Technologies LP bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $2,069,000. Versor Investments LP lifted its position in shares of Edwards Lifesciences by 102.5% during the 3rd quarter. Versor Investments LP now owns 4,455 shares of the medical research company’s stock worth $294,000 after buying an additional 2,255 shares during the last quarter. Addison Advisors LLC lifted its position in shares of Edwards Lifesciences by 915.1% during the 3rd quarter. Addison Advisors LLC now owns 18,038 shares of the medical research company’s stock worth $1,190,000 after buying an additional 16,261 shares during the last quarter. Finally, Patten & Patten Inc. TN lifted its position in shares of Edwards Lifesciences by 7.5% during the 3rd quarter. Patten & Patten Inc. TN now owns 164,904 shares of the medical research company’s stock worth $10,882,000 after buying an additional 11,512 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on EW. Oppenheimer restated an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Morgan Stanley restated an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Wolfe Research upgraded Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. Seventeen analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $75.67.

Edwards Lifesciences Trading Up 1.1 %

Shares of EW stock opened at $66.52 on Thursday. The stock has a market cap of $39.23 billion, a price-to-earnings ratio of 9.60, a PEG ratio of 3.70 and a beta of 1.12. The stock has a 50-day moving average of $67.47 and a 200-day moving average of $76.51. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the firm posted $0.59 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 41,250 shares of company stock valued at $2,744,438 over the last 90 days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.